Richard Hatchett | CEO

Richard Hatchett, CEO, CEPI

Richard J. Hatchett, MD, is Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI), a partnership of public, private, philanthropic and civil organizations that will finance and co-ordinate the development of vaccines against high priority public health threats and vaccine platform technologies to respond rapidly to emerging infectious diseases with pandemic or epidemic potential.
Prior to joining CEPI, Dr. Hatchett most recently served as acting Director of the U.S. Biomedical Advanced Research and Development Authority (BARDA), after serving for five years as BARDA’s Chief Medical Officer and Deputy Director.  At BARDA, Dr. Hatchett oversaw programs to develop medical countermeasures against chemical, biological, radiological and nuclear threats, pandemic influenza, and emerging infectious diseases and led or helped lead the development of vaccines, therapeutics, and diagnostics for a number of emerging viruses, including the H3N2v and H7N9 influenza viruses, MERS, Ebola, and Zika.  Previously, Dr. Hatchett served on the White House Homeland Security Council under President George W. Bush and was a member of the White House National Security Staff under President Barack Obama.  He is a recipient of the HHS Secretary’s Award for Distinguished Service and a five-time recipient of the NIH Director’s Merit Award.
A graduate of Vanderbilt University and the Vanderbilt University Medical School, he completed a residency in internal medicine at the New York Hospital – Cornell Medical Center and a fellowship in medical oncology at Duke University Medical Center. 


Day One 10th Oct Human, Vet, Immune @ 09:00

Opening plenary discussion: Creating a new strategy: How does the current global outbreak response system need to change?

Opening plenary discussion: Creating a new strategy: How does the current global outbreak response system need to change?
  • Efforts to develop an international fund to develop vaccines that are of low commercial interest but potentially epidemic-proof to the next emerging disease
  • Understanding the legal and regulatory framework for licensure of medical countermeasures during public health emergencies
  • How do we know which vaccines to stockpile? Initial efforts in MERS-CoV, Lassa and Nipah viruses
  • How should pharma and industry respond to developing low income vaccines?
  • What’s the global capacity and how fast can we develop a sustainable supply?

back to speakers